Katrine Wickstroem

Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers

Urs B. Hagemann, Christine Ellingsen, Joachim Schuhmacher et al. · Clinical Cancer Research · 2019 · 108 citations

Medicine, Oncology, Pharmacology +17

<i>In Vitro</i> and <i>In Vivo</i> Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia

Urs B. Hagemann, Katrine Wickstroem, Ellen Wang et al. · Molecular Cancer Therapeutics · 2016 · 80 citations

Medicine, Oncology, Pharmacology +17

Synergistic Effect of a Mesothelin-Targeted ²²⁷Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models

Katrine Wickstroem, Urs B. Hagemann, Véronique Cruciani et al. · Journal of Nuclear Medicine · 2019 · 51 citations · Full text

Medicine, Oncology, Pharmacology +17

Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model

Katrine Wickstroem, Jenny Karlsson, Christine Ellingsen et al. · Pharmaceuticals · 2019 · 36 citations · Full text

Medicine, Medicinal Chemistry, Oncology +17

Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344

Katrine Wickstroem, Urs B. Hagemann, Alexander Kristian et al. · International Journal of Radiation Oncology*Biology*Physics · 2019 · 27 citations · Full text

Medicine, Medicinal Chemistry, Oncology +6